Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 28, 2015 11:32 AM ET

Biotechnology

Company Overview of GlycoMimetics, Inc.

Company Overview

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company develops lead product rivipansel, a glycomimetic drug candidate that has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. It also develops GMI-1271, a specific E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers; and GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a ...

401 Professional Drive

Suite 250

Gaithersburg, MD 20879

United States

Founded in 2003

34 Employees

Phone:

240-243-1201

Fax:

240-243-1018

Key Executives for GlycoMimetics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 56
Total Annual Compensation: $417.0K
Chief Financial Officer and Principal Accounting Officer
Age: 41
Total Annual Compensation: $285.4K
Chief Medical Officer and Vice President of Clinical Development
Age: 47
Total Annual Compensation: $345.0K
Chief Scientific Officer, Vice President of Research and Director
Age: 62
Total Annual Compensation: $309.8K
Compensation as of Fiscal Year 2014.

GlycoMimetics, Inc. Key Developments

GlycoMimetics Announces Initiation of Phase 3 Clinical Trial Assessing the Efficacy and Safety of Rivipansel for the Treatment of Vaso-Occlusive

GlycoMimetics announced the initiation of a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in patients hospitalized with sickle cell disease in partnership with Pfizer Inc. The dosing of the first patient under this Phase 3 clinical trial has triggered the second of two milestone payments from Pfizer to GlycoMimetics totaling USD 35 million. Under the partnership, Pfizer dosed the first patient in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study, which is a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for treating vaso-occlusive crisis in patients hospitalized with sickle cell disease who are six years of age or older. In conjunction with the trial, the primary endpoint for the study will be time to readiness-for-discharge. Key secondary endpoints will include time to discharge, cumulative IV opioid consumption and time to discontinuation of IV opioids. Sickle cell disease is a genetic disease affecting people in the US, predominantly of African descent. One of the most severe complications of sickle cell disease is vaso-occlusive crisis, which is typically characterized by excruciating, debilitating pain that occurs periodically throughout the life of a person with sickle cell disease.

GlycoMimetics, Inc., Annual General Meeting, Jul 15, 2015

GlycoMimetics, Inc., Annual General Meeting, Jul 15, 2015., at 10:00 US Eastern Standard Time. Location: 9714 Medical Center Drive. Agenda: To elect the two nominees for director named herein to hold office until the 2018 annual meeting of stockholders; to ratify the selection by the audit committee of the board of directors of Ernst & Young LLP as the independent registered public accounting firm for its fiscal year ending December 31, 2015; and to conduct any other business properly brought before the meeting.

GlycoMimetics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:00 AM

GlycoMimetics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 10:00 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Armand Girard, Vice President of Corporate Development.

Similar Private Companies By Industry

Company Name Region
Traverse Biosciences, Inc. United States
Morphogenesis, Inc. United States
Microban Products Company United States
Genteric, Inc. United States
Novopyxis Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GlycoMimetics, Inc., please visit www.glycomimetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.